Freakonomics Radio
Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.
- SOURCES:
- Chris Snyder, professor of economics at Dartmouth College.
- David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.
- Heather Stone, health science policy analyst at the Food & Drug Administration.
- Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator.
- RESOURCES:
- Chasing My Cure: A Doctor’s Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019).
- Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016).
- Market Shaping Accelerator.
- CURE ID Registry.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
EXTRA: Why Quitting Is Usually Worth It
Stephen Dubner appears as a guest on Fail Better, a new podcast hosted by David Duchovny. The two of them trade stories about failure, and ponder the lessons that success could never teach. SOURCES:…
The University of Impossible-to-Get-Into (Update)
America’s top colleges are facing record demand. So why don’t they increase supply? (Part 2 of our series from 2022, “Freakonomics Radio Goes Back to School.”) SOURCES: Peter Blair, professor of education at Harvard…
What Exactly Is College For? (Update)
We think of them as intellectual enclaves and the surest route to a better life. But U.S. colleges also operate like firms, trying to differentiate their products to win market share and prestige points. In…
EXTRA: Here’s Why You’re Not an Elite Athlete (Update)
There are a lot of factors that go into greatness, many of which are not obvious. As the Olympics come to a close, we revisit a 2018 episode in which top athletes from a variety…
600. “If We’re All in It for Ourselves, Who Are We?”
Tania Tetlow, a former federal prosecutor and now the president of Fordham University, thinks the modern campus could use a dose of old-fashioned values. SOURCE: Tania Tetlow, president of Fordham University. RESOURCES: “Not…
599. The World’s Most Valuable Unused Resource
It’s not oil or water or plutonium — it’s human hours. We’ve got an idea for putting them to use, and for building a more human-centered economy. But we need your help. SOURCES: Nathan…
EXTRA: Why Rent Control Doesn’t Work (Update)
A new proposal from the Biden administration calls for a nationwide cap on rent increases. Economists think that’s a terrible idea. We revisit a 2019 episode to hear why. SOURCES: Tommy Andersson, professor of…
598. Is Overconsolidation a Threat to Democracy?
That’s the worry. Even the humble eyeglass industry is dominated by a single firm. We look into the global spike in myopia, how the Lemtosh got its name, and what your eye doctor knows that…
597. Why Do Your Eyeglasses Cost $1,000?
A single company, EssilorLuxottica, owns so much of the eyewear industry that it’s hard to escape their gravitational pull — or their “obscene” markups. Should regulators do something? Can Warby Parker steal market share? And…
EXTRA: People Aren’t Dumb. The World Is Hard. (Update)
You wouldn’t think you could win a Nobel Prize for showing that humans tend to make irrational decisions. But that’s what Richard Thaler has done. In an interview from 2018, the founder of behavioral economics…